Glaukos iStent inject W Trabecular Micro-Bypass System, Glaukos iStent inject W Trabecular Micro-Bypass System with
Glaukos Corporation · Decision date Oct 1, 2026
What did the FDA decide?
FDA posted a 30-Day Notice decision for supplement S023 to PMA P170043 for the Glaukos iStent inject W Trabecular Micro-Bypass System. The decision record lists four changes: moving the Instructions for Use from printed to electronic format, updating the sustainable shipper box, reducing the incoming inspection sampling plan for the Trocar component, and adding an alternative location for final packaging, labeling, and lot release operations on the existing manufacturing campus.
The supplement is categorized as a process change involving manufacturer, sterilizer, packager, or supplier. The posted statement does not describe any change to the device design, indications, or clinical data, and it does not provide evidence of safety or effectiveness. Specific details about the alternative location, the revised sampling plan parameters, or the shipper box update are absent from the source statement.
FDA approval order statement
four changes including Instruction for Use change from printed to electronic format, updated sustainable shipper box, reduced incoming inspection sampling plan for Trocar component, and addition of alternative location for final packaging, labeling and lot release operations on the existing manufacturing campus
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Oct 1, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170043/S023
- Regulatory pathway
- PMA supplement
- Applicant
- Glaukos Corporation
- Product code
- OGO
- Decision code
- OK30
- Decision date
- Oct 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intraocular pressure lowering implant.
- Applicant
- Glaukos Corporation
- Product code
- OGO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170043. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170043 · Original PMA
iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)
P170043/S023 received
Application receipt date recorded by FDA.
P170043/S023 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P170043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Glaukos Corporation | PMA approval | Jun 21, 2018 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Glaukos Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 229 Avenida Fabricante, San Clemente, CA, 92672
Sources and methodology
- Original FDA record: P170043/S023
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records